Tests UBT251 in adults living with overweight or obesity
Tests UBT251 against a placebo in adults living with overweight or obesity.
Plain-language title generated from the registry record
Registry title: A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity
Key facts
- Where
- Montreal, CanadaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07395687, who can take part
Where in Canada
- Altasciences Clinical Company, IncMontreal, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07395687
- Record updated
- 21 April 2026
- Original description
The purpose of this clinical study is to find out if UBT251 is safe and effective for treating people who are living with overweight or obesity. Participants will get either UBT251 (the treatment being tested) or Placebo (a treatment that has no active medicine in it), which treatment participants get is decided by chance.Read full original descriptionShow less
A Study Investigating Safety, Tolerability and Efficacy of UBT251 in Participants Living With Overweight or Obesity
The purpose of this clinical study is to find out if UBT251 is safe and effective for treating people who are living with overweight or obesity. Participants will get either UBT251 (the treatment being tested) or Placebo (a treatment that has no active medicine in it), which treatment participants get is decided by chance.
Inclusion: Male or female (sex at birth); For Part C: Japanese, Chinese or non-Asian participants (all self-reported):; For Japanese participants: both parents of Japanese descent; For Chinese participants: both parents of Chinese descent; For non-Asian participants: both parents of non-Asian descent (non-Asian is defined as of countries outside of Asia); Age at the time of signing the informed consent:; For Part A: 18-55 years (both inclusive); For Part B: 18-65 years (both inclusive); For Part C: 18-55 years (both inclusive); BMI at screening (overweight and obesity should be due to excess adipose tissue, as judged by the investigator):; For Part A: 27.0-39.9 kilogram per meter square (kg/m\^2) (both inclusive); For Part B: 30.0-50.0 kg/m\^2 (both inclusive); For Part C: 24-34.9 kg/m\^2 (both inclusive); Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG), and clinical laboratory tests performed during the screening visit, as judged by the investigator.
Exclusion: Known or suspected hypersensitivity to study intervention(s) or related products; Any condition, unwillingness or inability, which in the investigator's opinion might jeopardise the participant's safety or compliance with the protocol; Treatment with any marketed product containing compounds with glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) or glucagon receptor agonism within 90 days before screening.